VIDEO: Trastuzumab deruxtecan possible ‘new standard of care’ in second line HER2-positive metastatic breast cancer
Click Here to Manage Email Alerts
DESTINY-Breast03 data presented at the virtual ESMO Congress showed that trastuzumab deruxtecan significantly improved PFS compared with trastuzumab emtansine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.
Trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) demonstrated “a pretty dramatic improvement in outcomes” compared with trastuzumab emtansine (T-DM1; Kadcyla, Genentech) as well as a manageable safety profile, Ian E. Krop, MD, PhD, associate chief in the division of breast oncology at the Susan F. Smith Center for Women's Cancers and clinical research director at the Breast Oncology Center at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, told Healio in a video interview.
“The hazard ratio was 0.28, which means essentially that there were 72% fewer progression events or deaths in the trastuzumab deruxtecan arm, which is kind of a crazy number,” Krop said. “I think it’s going to be hard not to conclude that trastuzumab deruxtecan should become the new standard of care for the vast majority of patients in the second-line setting.”
Collapse
Cortés J, et al. Abstract LBA1. Presented at: European Society for Medical Oncology Congress (virtual meeting); Sept. 16-21, 2021.
Click Here to Manage Email Alerts